Search
pirfenidone (Deskar, Esbriet)
Indications:
- treatment of idiopathic pulmonary fibrosis [1,2] (NICE)
* slows progression of disease on pulmonary function tests [3]
* does not elevate patients' perceived quality of life [3]
Contraindications:
- end-stage renal disease
- liver failure [2]
Dosage:
- 2400 mg PO QD (may be in divided doses) [1]
- take with food to minimize nausea, dizziness
Adverse effects:
- nausea
- dizziness [2]
- rash
- fatigue
- diarrhea
- dyspepsia, abdominal pain
- photosensitivity, propensity to sunburn [2]
- upper respiratory tract infection
- headache
- anorexia
- GERD
- sinusitis
- insomnia
- weight loss
- arthralgia
Mechanism of action:
- anti-fibrotic agent
General
pulmonary agent
aromatic compound
Database Correlations
PUBCHEM cid=40632
References
- King TE et al
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic
Pulmonary Fibrosis.
N Engl J Med. May 18, 2014
PMID: 24836312
http://www.nejm.org/doi/full/10.1056/NEJMoa1402582
- FDA News Release. October 15, 2014.
FDA approves Esbriet to treat idiopathic pulmonary fibrosis.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm
- Dempsey TM, Sangaralingham LR, Yao Xet al.
Clinical effectiveness of antifibrotic medications for idiopathic
pulmonary fibrosis.
Am J Respir Crit Care Med 2019 Jul 15; 200:168
PMID: 31150266
https://www.atsjournals.org/doi/10.1164/rccm.201902-0456OC